Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MYLAN LABORATORIES LIMITED et al v. FOOD AND DRUG ADMINISTRATION et al
Case Number:
1:12-cv-01637
Court:
Nature of Suit:
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
January 02, 2013
Ranbaxy Foils Mylan's Challenge To Valsartan Exclusivity
A Washington federal judge on Thursday tossed Mylan Pharmaceuticals Inc.'s suit against the U.S. Food and Drug Administration that attempted to gain marketing approval for its generic hypertension drug valsartan, saying Ranbaxy Laboratories Ltd.'s first-to-file exclusivity for the generic remains intact.
-
December 07, 2012
Mylan Claims Ranbaxy Sitting On Hypertension Drug Exclusivity
Mylan Pharmaceuticals Inc. told a Washington federal judge on Friday that it should be allowed to start marketing a generic version of its hypertension drug valsartan, alleging Ranbaxy Laboratories Ltd. has forfeited its exclusivity rights by not actively pursuing U.S. Food and Drug Administration approval.
-
October 15, 2012
Ranbaxy Wants In On Mylan's Suit Over Valsartan Exclusivity
Ranbaxy Laboratories Ltd. on Friday asked a Washington federal court to allow it to intervene in a Mylan Pharmaceuticals Inc. generic exclusivity dispute with the U.S. Food and Drug Administration over hypertension drug valsartan, saying only it could properly defend its exclusive rights to the drug.
-
October 02, 2012
Mylan Knocks Ranbaxy's Exclusivity Right For Valsartan
Mylan Pharmaceuticals Inc. on Tuesday hit the U.S. Food and Drug Administration with a lawsuit objecting to its award of a 180-day exclusivity period to Ranbaxy Pharmaceuticals Inc. for the marketing of a generic version of hypertension drug valsartan.